Vertex will buy Alpine Immune Sciences for $4.9B in another big Seattle biotech deal by Todd Bishop & Taylor Soper on April 10, 2024April 10, 2024 at 6:05 pm Boston-based biotech company Vertex Pharmaceuticals agreed to acquire Seattle-based Alpine Immune Sciences for $65 per share, totaling about $4.9 billion in cash, a 38% premium over Alpine’s closing price on… Read More